Valuation dashboard for Viatris Inc. (VTRS) with P/E N/A, P/B 1.44, EV/EBITDA -70.63 and dividend yield 2.73%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs).
Analysis Summary
Viatris Inc. reported revenue of $14.30B in the most recent fiscal year, growing at a 5-year CAGR of 3.7%.
Trailing-twelve-month margins: gross margin 34.8%, operating margin -0.6%, net margin -2.8%.
At the current price of $17.62, VTRS has negative trailing earnings (P/E not meaningful) and an ROE of -23.89%. Market capitalisation stands at $20.5B, placing it among large-cap names.
Balance sheet quality for VTRS: current ratio of 1.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.44 |
| EV / EBITDA | -70.63 |
| Dividend Yield | 2.73% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| VTRS | Viatris Inc. | $20.5B | 1.44 | -23.9% | |
| MRNA | Moderna, Inc. | $75.4B | 11.13 | -39.2% | |
| BBIO | BridgeBio Pharma, Inc. | $12.9B | 31.7% | ||
| NBIX | Neurocrine Biosciences, Inc. | $14.3B | 20.31 | 3.92 | 21.1% |
| IONS | Ionis Pharmaceuticals, Inc. | $7.7B | 16.38 | -77.9% | |
| ELAN | Elanco Animal Health Incorporated | $11.2B | 1.68 | -3.0% | |
| RDY | Dr. Reddy's Laboratories Limited | $10.2B | 30.37 | 2.62 | 12.2% |
| BAX | Baxter International Inc. | $12.1B | 1.96 | -16.6% |
Price
| Price | $17.62 |
| Market Cap | $20.5B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -23.89% |
| Return on Invested Capital | -7.95% |
| Return on Assets | -9.45% |
| Gross Margin | 34.83% |
| Operating Margin | -0.59% |
| Net Margin | -2.79% |
Related companies: BAX · BBIO · ELAN · EXAS · IONS · MRNA · NBIX
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of VTRS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks